Search bioRxiv⌕ Search

Biology subjects

Udumanne, T.

Publications and source records attributed to Udumanne, T..

2 recordsLinked to original sources

Integrated analysis of ribosomal DNA copy number and methylation using nanopore long-read sequencing

Ribosomal RNA (rRNA) provides the structural and catalytic core of ribosomes and is encoded by ribosomal RNA genes (rDNA) arranged in tandem repeat arrays. rDNA copy number (CN) is highly dynamic, representing a clinically relevant form of structural variation, but its accurate quantification has been challenging due to its highly repetitive and GC-rich nature. Here, we present RICO (Ribosomal DNA Integrated Copy Number and Methylation Analysis), a novel computational pipeline for integrated estimation of rDNA CN and methylation using nanopore long-read sequencing. RICO leverages long sequencing reads that span entire rDNA repeats, mapped to an rDNA-augmented reference genome, and normalizes coverage using an array of single-copy genes. We show that RICO provides accurate rDNA CN estimates in simulated datasets and reproducible measurements across human samples, with strong agreement to short-read sequencing and PCR-based methods. As biological validation, RICO detects a [~]40% reduction in rDNA CN in Atrx-knockout mouse cells, consistent with established effects of ATRX loss on rDNA CN, and captures detected increased total and active rDNA CN in malignant cells from a MYC-driven B-cell lymphoma mouse model, in line with prior psoralen-based chromatin studies. Applying RICO to independent human cohorts, we uncover that individuals with higher total rDNA CN consistently exhibited higher fractions of high-methylated rDNA copies, suggesting a dosage compensation mechanism that potentially maintains a similar number of active rDNA copies across individuals. Together, RICO enables integrated analysis of rDNA CN and methylation state, providing a scalable framework for investigating rDNA regulation across population and disease studies.

bioinformatics↗

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.

Ribosome biogenesis (RiBi) is a key determinant of cell growth and proliferation and is highly elevated in cancer due to the activation by oncogenes such as MYC. First-generation RiBi inhibitor CX-5461, while demonstrating clinical potential for cancer treatment, also induces DNA damage through off-target inhibition of TOP2 and potentially other mechanisms, bringing into question RiBi as a target for cancer therapy. In this study, we test second-generation RiBi inhibitor, PMR-116. PMR-116 exhibits improved drug-like properties compared to first-generation RiBi inhibitors and has robust anti-tumour activity in the absence of global DNA damage signalling in a broad range of pre-clinical models of haematologic and solid cancers, particularly in malignancies where MYC is either the driver of disease or is elevated. Thus, our work demonstrates that RiBi is a genuine target for cancer therapy and highlights the potential to exploit a critical therapeutic vulnerability in high-MYC human cancers with dismal therapeutic outcomes. Statement of significanceDespite the development of new cancer therapies, most advanced malignancies remain incurable. We demonstrate that PMR-116, a second-generation RiBi inhibitor, has robust therapeutic efficacy in preclinical models of cancer, offering great promise to treat a broad spectrum of human solid and haematologic malignancies, especially where MYC is a driver.

cancer biology↗